Skip to Content
MilliporeSigma
All Photos(1)

Documents

SML0123

Sigma-Aldrich

Deflazacort

≥98% (HPLC)

Synonym(s):

(11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 11β,21-dihydroxy-2′-methyl-5′βH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 2′-acetate, DL-458-IT, L-5458, azacort, oxazacort, pregna-1,4-diene-11β,21-diol-3,20-dione[17α,16α-d]-2′-methyloxazoline 21-acetate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C25H31NO6
CAS Number:
14484-47-0
Molecular Weight:
441.52
EC Number:
238-483-7
MDL number:
MFCD00866106
UNSPSC Code:
51111800
PubChem Substance ID:
329825173
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

color

white to tan

solubility

DMSO: ≥20 mg/mL

storage temp.

2-8°C

SMILES string

CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]23C

InChI

1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1

InChI key

FBHSPRKOSMHSIF-GRMWVWQJSA-N

Gene Information

human ... NR3C1(2908)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Deflazacort is an anti-inflammatory and immunosuppressant glucocorticoid.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Elaine C da Silva et al.
Arquivos de neuro-psiquiatria, 70(3), 191-195 (2012-03-07)
To assess the evolution of motor function in patients with Duchenne muscular dystrophy (DMD) treated with steroids (prednisolone or deflazacort) through the Motor Function Measure (MFM), which evaluates three dimensions of motor performance (D1, D2, D3). Thirty-three patients with DMD
Elena Stacy Mazzone et al.
PloS one, 8(1), e52512-e52512 (2013-01-18)
The aim of the study was i) to assess the spectrum of changes over 24 months in ambulant boys affected by Duchenne muscular dystrophy, ii) to establish the difference between the first and the second year results and iii) to
Corrado Angelini et al.
Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology, 31(1), 9-15 (2012-06-05)
Steroids have been used since two decades and several trials were conducted to establish their efficacy in DMD patients with various regimens. The clinical outcomes showed increased function in the treated boys, and in a single trial with deflazacort, prolongation
Meilan M Rutter et al.
Neuromuscular disorders : NMD, 22(12), 1046-1056 (2012-09-13)
This study evaluated efficacy and safety of growth hormone treatment in Duchenne muscular dystrophy boys with glucocorticoid-induced growth failure. We reviewed 39 consecutive boys (average age 11.5 years; 32 ambulatory) treated with growth hormone for 1 year during a four-year
A L Mayo et al.
Neuromuscular disorders : NMD, 22(12), 1040-1045 (2012-07-25)
Quality of life in Duchenne Muscular Dystrophy (DMD) has improved significantly with corticosteroid treatment. However, corticosteroids decrease bone mass and increase vertebral fragility fracture risk. We report on bone health in 39 boys with DMD on long-term deflazacort (0.9 mg/kg/day)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service